Tirzepatide 10 mg is the entry-strength lyophilised vial in the BuyRetaUK Tirzepatide range — a compact 10-milligram presentation of LY3298176 sized for short in-vitro workflows, method-development runs and small-scale pilot studies where minimal peptide mass avoids over-aliquoting.
Tirzepatide 10 mg is a 10-milligram lyophilised LY3298176 vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the smallest presentation in the BuyRetaUK Tirzepatide range, chosen for short in-vitro pilots, method development and low-volume comparative work.
Tirzepatide 10 mg is a single lyophilised vial containing 10 milligrams of Tirzepatide (LY3298176), a synthetic dual receptor agonist active at the GLP-1 and GIP receptors. It is the smallest presentation stocked at BuyRetaUK and the appropriate first choice for laboratories running short, well-scoped in-vitro protocols.
For receptor pharmacology and mechanism see Tirzepatide Mechanism of Action; for the cornerstone explanatory guide see What is Tirzepatide?.
The natural step up is the Tirzepatide 20 mg vial — twice the packaged mass at a lower per-milligram cost, typically the right call once a study will consume more than one 10 mg vial. For sustained programmes, the Tirzepatide 40 mg vial consolidates a workflow onto fewer batches. All three are released to the same specification; only the packaged mass differs. The Strengths Hub lays out the full ladder side by side.
Every vial ships with a batch-specific COA · UK dispatch
The 10 mg vial is released under the same synthesis and analytical framework as every other stocked Tirzepatide strength — see the laboratory quality page for methodology and acceptance criteria.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Every 10 mg vial ships with a batch-specific Certificate of Analysis reporting HPLC-UV purity, identity, appearance and where applicable moisture and endotoxin. Cross-check the batch number on the vial against the verification library — for a section-by-section walk-through of the certificate, see the Certificate of Analysis guide.
The 10 mg vial is released against the same ≥99% HPLC-UV area-percent specification as the 20 and 40 mg presentations, with orthogonal identity confirmation by mass spectrometry. Method detail — chromatography theory, impurity reporting — lives in the Tirzepatide Purity reference.
Store sealed 10 mg vials at 2–8 °C short-term and at −20 °C for extended holding. Reconstituted working stock in bacteriostatic water is refrigerated at 2–8 °C and typically used within four to six weeks. Full cold-chain framework in the Tirzepatide Storage & Reconstitution guide.
10 mg suits short or single-run protocols — for extended studies, step up to 20 mg or 40 mg.
Decide diluent volume before opening the vial; a 10 mg cake is easily over-diluted.
Cross-reference the vial batch number against the published Certificate of Analysis before use.
Prepare 2–8 °C storage and single-use aliquot tubes before reconstitution.
It is the smallest presentation BuyRetaUK stocks — a compact peptide mass that suits laboratories running short in-vitro pilots, refining assay conditions or evaluating LY3298176 against comparators where a partially used higher-strength vial would be wasteful.
Reconstituting a 10 mg vial in 1 mL of bacteriostatic water yields 10 mg/mL; in 2 mL yields 5 mg/mL; in 5 mL yields 2 mg/mL. The reconstitution calculator returns the exact diluent volume for any target concentration.
Yes. A single 10 mg vial typically supplies enough peptide to establish chromatographic parameters, verify reconstitution technique and run assay-condition scans before a study is scaled onto larger vials.
Choose 20 mg once a protocol will consume more than one 10 mg vial's worth of peptide, or when a single larger reconstitution simplifies workflow. Both share the same ≥99% HPLC-UV release specification — per-milligram economics generally favour the larger vial for anything beyond a pilot.
No. Every stocked Tirzepatide strength is manufactured under the same synthesis and release framework, with identical HPLC-UV purity and ESI-MS identity confirmation reported on the batch-specific Certificate of Analysis.
Yes. Reconstituted stock can be aliquoted into single-use portions and frozen; freeze once and thaw once per aliquot. The Tirzepatide storage guide covers freeze-thaw handling in detail.
No. All BuyRetaUK Tirzepatide vials, including the 10 mg entry vial, are supplied for in-vitro laboratory research only and are not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Dual GIP/GLP-1 receptor overview and research framing.
How dual receptor engagement drives the incretin response.
Published evidence base, SURPASS & SURMOUNT programmes, laboratory applications.
Phase 3 SURPASS & SURMOUNT read-outs and the peer-reviewed literature.
Dual vs triple incretin agonist — how they differ.
HPLC purity and Certificate of Analysis verification.
Lyophilised storage, bacteriostatic water reconstitution, in-use stability.
Every tirzepatide vial strength available.
UK commercial hub — lab data, COAs and dispatch.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →How to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideA laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Tirzepatide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →
